Watch the latest episode of focusIR Fireside Chats: Why Edinburgh Investment Trust Is Backing Turnaround Stocks for 2026 Growth. Viewhere

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSPE.L Regulatory News (SPE)

  • There is currently no data for SPE

Accolade Release 11.2

6 Jul 2017 07:00

RNS Number : 2492K
Sopheon PLC
06 July 2017
 

SOPHEON PLC

("Sopheon" or the "Company")

 

Sopheon's Accolade 11.2 Introduces New Analytics Capabilities to Enable Actionable Insights

 

Sopheon, the international provider of software, expertise, and best practices for Enterprise Innovation Management, announces today the latest version of its Accolade® Enterprise Innovation Management (EIM) solution.

'Good' decisions are based on the availability of 'good' information - having meaningful, trusted and current data at your fingertips at the moment you need it. Business leaders driving decision-centric processes should be drawing on comprehensive information that is generated internally as well as gleaned from outside the company. Sopheon has long focused on surfacing relevant and timely information to support better, faster decisions; with the release of Accolade version 11.2, Sopheon offers new analytic and knowledge discovery capability to more proactively manage risk and create breakthrough innovations with increased efficiency. The new capability - named Accolade Insights - offers a range of benefits.

Further Connecting the Enterprise

Speed to informed decisions, critical in a fast-moving, digital business environment, depends on data that is timely, accurate, situationally aware and actionable. Accolade Insights automatically leverages and connects internal and external data sources to proactively consolidate and serve up intellectual 'assets' at the point a decision needs to be made. These assets include relevant experts and expertise, learnings from past work, and external macroeconomic changes impacting critical assumptions underpinning business forecasts and key performance indicators.

Pre-empting Risk and Improving Accuracy of Business Forecasts

Accolade Insights was designed to help companies leverage internal data in combination with macroeconomic and other external factors for real-time monitoring of the health status of products, portfolios and projects, including the business case assumptions impacting accuracy of revenue and profit forecasts. This is equally applicable to the management of new product introductions, in-market products, product lines and market segments.

When shown a preview of this functionality, a $14 billion industrial manufacturing customer stated: "Some time ago we had what we thought was a great innovation, but the macroeconomics shifted in the middle of our product development cycle. In the end we went to market with a product that failed because we didn't proactively adjust to the shift. Had I had this early visibility of the business case impact of the market dynamics, it would have saved us millions of dollars."

Stimulating Innovation & Improving Efficiency through Proactive Knowledge Reuse

Many companies encounter redundancy of innovation effort. They waste time and money on duplicating work that has been done before; recreating experience that has been 'lost' when key employees have left, repeating the same mistakes project after project because lessons learned are not codified and shared; or not being aware of technology or other developments that could be reused to shorten the time required to develop breakthrough innovations. Accolade automatically captures cross-functional work activity and work product, which become a rich asset for reuse.

One long-standing Sopheon customer proudly relates how a breakthrough technology developed by a packing business unit to retain freshness in bags of crisps, was successfully reused for entirely different applications in aero and auto by another division, generating millions in new revenue. The 'discovery' of the technology that was reused was enabled through Accolade.

 

Sopheon's CEO Andy Michuda, said: "Sopheon has long focused on making relevant and timely information available to support better, faster decisions. Accolade 11.2 automatically leverages and connects internal and external data sources through Accolade Insights, allowing customers to proactively manage risk and create breakthrough innovations with more efficiency."

 

 

 

Sopheon® and Accolade® are trademarks of Sopheon 

 

 

 

 

For further information contact:

Barry Mence, ChairmanArif Karimjee, CFO

Sopheon plc

+ 44 (0) 1276 919 560

Carl Holmes / Giles Rolls (corporate finance)

Mia Gardener (corporate broking)

finnCap Ltd

+ 44 (0) 20 7220 0500

 

 

About Sopheon. Sopheon (LSE: SPE) partners with customers to provide complete Enterprise Innovation Management solutions including software, expertise, and best practices, that enable them to achieve exceptional long-term revenue growth and profitability. Sopheon's Accolade solution provides unique, fully-integrated coverage for the entire innovation management and new product development lifecycle, including strategic innovation planning, roadmapping, idea and concept development, process and project management, portfolio management and resource planning. Sopheon's solutions have been implemented by over 200 customers with over 60,000 users in over 50 countries. Sopheon is listed on AIM, operated by the London Stock Exchange. For more information, please visit www.sopheon.com.

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
NRAOKPDBABKDPOK
Date   Source Headline
3rd Nov 202310:15 amRNSForm 8.5 (EPT/NON-RI)
3rd Nov 20238:54 amRNSForm 8.3 - Rivomore Limited - Sopheon plc
2nd Nov 20239:34 amRNSForm 8.5 (EPT/NON-RI)
1st Nov 20233:44 pmEQSForm 8.3 - Apex Fundrock Limited : Form 8.3 Apex Fundrock Limited Re: Sopheon PLC
1st Nov 20231:55 pmRNSForm 8.3 - Sopheon plc
1st Nov 202311:23 amRNSForm 8.5 (EPT/NON-RI)
1st Nov 202310:51 amGNWForm 8.3 - [Sopheon plc - Opening Declaration - 31 03 2023] - (CGAML)
1st Nov 202310:35 amRNSForm 8.3 - Sopheon PLC
31st Oct 20231:00 pmRNSStatement re Possible Offer
24th Aug 20237:00 amRNSInterim Results
10th Jul 20237:00 amRNSAcquisition
15th Jun 20235:06 pmRNSIssue of Equity
8th Jun 20231:35 pmRNSResult of AGM
8th Jun 20237:00 amRNSAGM Statement
13th Apr 20234:20 pmRNSIssue of Equity
31st Mar 20239:14 amRNSIssue of Equity
27th Mar 20234:23 pmRNSDirector Shareholdings
24th Mar 20237:00 amRNSDirector Share Purchases
23rd Mar 20237:00 amRNSFinal Results
22nd Feb 20234:59 pmRNSIssue of Equity
6th Feb 20237:00 amRNSDirectorate Change and Notice of Results
30th Jan 20237:00 amRNSTrading Update
20th Sep 202212:01 pmRNSSopheon launches Acclaim Line of SaaS Offerings
2nd Sep 202210:06 amRNSIssue of Equity
1st Sep 20227:00 amRNSNew Release of Award-winning Innovation Product
24th Aug 20227:00 amRNSInterim Results
16th Aug 20227:00 amRNSFive-year, $11.2m Enterprise Agreement
3rd Aug 202210:18 amRNSHolding(s) in Company
21st Jun 202212:20 pmRNSHolding(s) in Company
9th Jun 20222:30 pmRNSResult of AGM
9th Jun 20227:00 amRNSAGM Statement
6th Jun 20226:02 pmRNSIssue of Equity & TVR
23rd May 20227:00 amRNSDirector Dealing & Issue of Equity
18th May 20227:00 amRNSAcquisition
29th Apr 20225:12 pmRNSHolding(s) in Company
7th Apr 20227:00 amRNSNew Sopheon Software Release
1st Apr 202212:10 pmRNSDirector Shareholdings
24th Mar 20227:00 amRNSFinal Results
25th Jan 20227:00 amRNSTrading Update
17th Jan 20223:15 pmRNSIssue of Equity
20th Dec 20217:00 amRNSAcquisition and Trading Update
24th Sep 20211:52 pmRNSIssue of Equity
16th Sep 202110:00 amRNSHolding(s) in Company
13th Sep 20215:24 pmRNSIssue of Equity
31st Aug 20216:14 pmRNSDirector Shareholdings
25th Aug 20217:00 amRNSInterim Results
13th Jul 20217:00 amRNSNew Release Drives Business Transformation
23rd Jun 20217:00 amRNSSopheon Earns Authority to Operate for NAVSEA
15th Jun 20219:54 amRNSIssue of Equity
10th Jun 202111:43 amRNSResult of AGM

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.